Alimera Sciences, Inc. (NASDAQ:ALIM – Get Rating) – Stock analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for shares of Alimera Sciences in a report issued on Tuesday, May 16th. HC Wainwright analyst Y. Chen expects that the biopharmaceutical company will earn ($0.34) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Alimera Sciences’ current full-year earnings is ($1.08) per share. HC Wainwright also issued estimates for Alimera Sciences’ Q2 2024 earnings at ($0.06) EPS, Q3 2024 earnings at $0.03 EPS, Q4 2024 earnings at $0.22 EPS and FY2024 earnings at ($0.14) EPS.
Several other equities analysts also recently issued reports on the company. Craig Hallum cut their target price on Alimera Sciences from $18.00 to $8.00 in a research report on Monday, April 3rd. StockNews.com started coverage on Alimera Sciences in a research report on Tuesday. They issued a “hold” rating on the stock.
Alimera Sciences Price Performance
Insiders Place Their Bets
In other Alimera Sciences news, major shareholder Alto Investors Lp Palo sold 200,919 shares of the stock in a transaction dated Friday, March 24th. The stock was sold at an average price of $1.56, for a total transaction of $313,433.64. The sale was disclosed in a filing with the SEC, which is available through this link. 12.90% of the stock is owned by insiders.
Institutional Investors Weigh In On Alimera Sciences
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC acquired a new stake in shares of Alimera Sciences during the 4th quarter valued at about $32,000. Susquehanna International Group LLP acquired a new stake in shares of Alimera Sciences during the 4th quarter valued at about $92,000. Renaissance Technologies LLC grew its position in shares of Alimera Sciences by 2.3% during the 2nd quarter. Renaissance Technologies LLC now owns 127,693 shares of the biopharmaceutical company’s stock valued at $698,000 after acquiring an additional 2,900 shares during the period. Finally, Caligan Partners LP acquired a new stake in shares of Alimera Sciences during the 4th quarter valued at about $1,297,000. 24.58% of the stock is owned by institutional investors and hedge funds.
Alimera Sciences Company Profile
Alimera Sciences, Inc engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion.
- Get a free copy of the StockNews.com research report on Alimera Sciences (ALIM)
- 5 Best Bank ETFs to Buy Now
- How to Invest in Telehealth and Telemedicine Stocks
- Target’s Guidance Looms Over The Market
- Want Clean Energy? Siemens May Be Pointing To A Breakout
- Up Over 2,600% in 5 Years, Wall Street Still Calls Celsius a Buy
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.